XTX Topco Ltd Raises Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Key Points

• XTX Topco Ltd increased its stake in Collegium Pharmaceutical by 159.2% in Q1, now holding 21,317 shares valued at approximately $636,000.
• Collegium Pharmaceutical announced a stock buyback plan allowing for the repurchase of $150 million in shares, indicating the company's belief that its stock is undervalued.
• In its latest earnings report, Collegium missed EPS expectations by $0.01, despite a revenue growth of 22.7% year-over-year, reporting $177.76 million for the quarter.

XTX Topco Ltd boosted its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 159.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,317 shares of the specialty pharmaceutical company's stock after purchasing an additional 13,092 shares during the quarter. XTX Topco Ltd owned approximately 0.07% of Collegium Pharmaceutical worth $636,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Wealthquest Corp purchased a new position in shares of Collegium Pharmaceutical in the 1st quarter valued at about $62,000. Virtus Fund Advisers LLC lifted its position in Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock worth $69,000 after acquiring an additional 565 shares during the period. FORA Capital LLC acquired a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $223,000. Allspring Global Investments Holdings LLC acquired a new stake in Collegium Pharmaceutical during the 1st quarter worth approximately $244,000. Finally, Brevan Howard Capital Management LP acquired a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $281,000.

Insider Buying and Selling

In related news, Director John Gordon Freund sold 6,601 shares of Collegium Pharmaceutical stock in a transaction on Monday, June 9th. The stock was sold at an average price of $30.62, for a total value of $202,122.62. Following the transaction, the director owned 70,658 shares in the company, valued at approximately $2,163,547.96. This trade represents a 8.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.51% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on COLL. Wall Street Zen raised Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Saturday. Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 price objective (up from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $43.75.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL traded up $1.99 during trading on Friday, reaching $34.93. The company had a trading volume of 809,607 shares, compared to its average volume of 307,794. The stock has a 50-day moving average price of $30.76 and a two-hundred day moving average price of $29.66. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The stock has a market capitalization of $1.12 billion, a PE ratio of 33.59 and a beta of 0.68. The company has a current ratio of 1.33, a quick ratio of 1.01 and a debt-to-equity ratio of 3.54.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by ($0.01). The firm had revenue of $177.76 million for the quarter, compared to analysts' expectations of $174.96 million. Collegium Pharmaceutical had a net margin of 5.13% and a return on equity of 97.28%. The business's quarterly revenue was up 22.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.45 EPS. As a group, sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical announced that its board has initiated a stock repurchase program on Monday, July 7th that allows the company to buyback $150.00 million in shares. This buyback authorization allows the specialty pharmaceutical company to purchase up to 15.4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its shares are undervalued.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.